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For many years, medical drug discovery has extensively exploited peptides as lead compounds. Currently, novel structures of therapeutic
peptides are derived from active pre-existing peptides or from high-throughput screening, and optimized following a rational drug design
approach. Molecules of interest may prove their ability to influence the disease outcome in animal models and must respond to a set of criteria
based on toxicity studies, ease of administration, the cost of their synthesis, and logistic for clinical use to validate it as a good candidate in a
therapeutic perspective. This applies to the potential use of peptides to target one central intracellular organelle, the mitochondrion, to modulate
(i.e. activate or prevent) apoptosis. Putative mitochondrial protein targets and the strategies already elaborated to correct the defects linked to these
proteins (overexpression, inactivation, mutation…, etc.) are described, and recent advances that led or may lead to the conception of therapeutic
peptides via a specific action on these mitochondrial targets in the future are discussed.
© 2006 Elsevier B.V. All rights reserved.Keywords: Peptides; Mitochondrion; Permeability transition; Apoptosis; Bcl-21. Introduction
For many years, some natural peptides and synthetic
derivatives are successfully used as therapeutic drugs to treat
chronic human pathologies [1]. For instance, this includes
peptides as diverse as GnRH for prostate cancer, insulin and
glucagon for diabetes type I and II, β-amyloid peptide for
Alzheimer's disease, T-20 (pentafuside) a synthetic 36-mer
peptide for HIV cell entrance inhibition, calcitonin for
osteoporosis, as well as vaso-intestinal peptide (VIP) for theAbbreviations: ANT, adenine nucleotide translocator; Cyt c, cytochrome c;
ΔΨm, mitochondrial transmembrane potential; HK, hexokinase; MMP,
mitochondrial membrane permeabilization; MUP, 4-methylumbelliferyl phos-
phate; IM, inner membrane; OM, outer membrane; ROS, reactive oxygen
species; PTPC, permeability transition pore complex; PBR, peripheral
benzodiazepine receptor; VDAC, voltage-dependent anion channel; Vpr, Viral
protein R
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doi:10.1016/j.bbabio.2006.07.002treatment of erectile dysfunction. The current approach to
design therapeutic peptides is to derive novel structures from
active pre-existing peptides or from high-throughput screening,
to modify it until optimization for a particular pathology
following the so-called rational drug design approach [1]. Thus,
independently of its origin or its mode of conception, the
molecule of interest should prove its ability to influence the
disease outcome in animal models and respond to a set of
criteria based on toxicity studies, ease of administration, the cost
of their synthesis, and the cost in clinical use to validate it as a
good candidate in a pharmacological perspective.
This review focuses on the potential use of peptides to
target one central intracellular organelle, the mitochondrion, to
modulate (i.e. activate or prevent) apoptosis [2], a form of cell
death that has been shown to play a critical role in most
human diseases [3]. Thus, it is generally admitted that cells die
by several mechanisms, two main of which being necrosis or
apoptosis, that can be accompanied by autophagy. In necrosis,
the application of a toxic stimulus onto a cell overwhelms its
homeostatic balance, committing the cell in an uncontrolled
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degradation of long-lived proteins and the cytoplasmic
organelles by the cell's own lysosomal system [5]. Genetic
or pharmacological deregulation of the autophagic process can
lead to cell death [6–8] and the term “autophagic cell death”
describes a form of programmed cell death morphologically
distinct from apoptosis and presumed to result from excessive
levels of cellular autophagy [9–12]. Apoptosis, is the best-
understood mechanism of controlled cell death, which is
regulated by an evolutionarily conserved cellular pathway that
consists in the caspase family, the Bcl-2 family, and the
adaptor protein Apaf-1 [13]. Apoptosis is a strictly regulated
removal of unwanted, damaged or mutated cells without a
deleterious inflammatory response of the organism [2]. In
some settings, autophagy and apoptosis may be interconnected
and mitochondria may be central organelles integrating the
two types of cell death [14,15]. Thus, a cell can be provoked
into apoptosis through a disruption of the balance between the
receipt of positive and negative signals, acting on the interplay
between endogenous inhibitors and activators of the apoptosis
pathway.
To illustrate the interest of targeting the mitochondrion for
apoptosis modulation, we will overview some of the putative
mitochondrial proteic targets and the strategies already elabo-
rated to correct the defects linked to these proteins (over-
expression, inactivation, mutation…, etc.). Finally, we will
discuss recent advances that led or may lead to the conception of
therapeutic peptides via a specific action on these mitochondrial
targets.
2. The modulation of apoptosis via the mitochondrion
The idea of a mitochondrial basis for killing tumor cells has
emerged from Warburg hypothesis [16], that is built-up on the
general differences in metabolic control occurring between
cancer and normal cells. Subsequently, deregulation of
programmed cell death or apoptosis has been related to the
development of cancer [17], and mitochondria have been
identified as gatekeepers or integrators in many apoptotic-
signaling pathways [18–20] establishing a link between
“cancer/metabolism/apoptosis/mitochondrion” [21]. This
opened the path to a promising future for innovative
apoptosis-based therapies of cancer [22,23]. In numerous
experimental systems, the apoptosis process can be divided
into three different stages (for review, see [24]. The induction
phase corresponds to the convergence onto the mitochondrion
of heterogeneous induction pathways triggered by various
stimuli (radiation, receptor ligation, genotoxic stress, hypoxia,
oncogene activation and chemotherapy…). The following
decision phase is controlled by oncogenes and anti-oncogenes
of the Bax/Bcl-2 family and manifests as a change in
mitochondrial membrane permeability (MMP), which in turn
is responsible for the last degradation phase of apoptosis and
cell dismantling [24,25]. MMP may occur via several mechan-
isms (Fig. 1), which include Bax or Bak oligomerization in the
outer mitochondrial membrane to form a pore that allows the
release of cytochrome c (Cyt c), the opening of (poly)proteincomplexes, such as the ATP-dependent potassium channel
(mtK-ATP [26,27] and the permeability transition pore complex
(PTPC; [28,29]). In various pathways of apoptosis, MMP
involves the permeabilization of the OM via the formation of
channels composed of resident mitochondrial proteins (VDAC,
Bak, MAC…) and/or cytosolic proteins that have translocated to
mitochondrial membranes (Bax, Bid, Bad …) in a complex
interplay with resident proteins such as Bak and Bcl-2 [30].
Under such MMP mechanism, one class of BH3-only proteins
(for instance Bid and Bim) are required to activate Bax and Bak
pore-forming activity in the OM, and another class of BH3-only
proteins (for instance Bad and Bik) may bind Bcl-2 displacing
sequestered Bid [30–32]. Such selective binding by BH3 only
proteins for particular multidomain prosurvival or proapoptotic
BH protein suggest that highly specific drugs can be found. The
extensive study of the MMP process revealed that mitochondria
contain several therapeutic targets (for reviews, see [33–35].
Indeed, MMP (i) is rate limiting for the induction of cell death
irrespective of the primary site or organelle affected (plasma
membrane, nucleus, endoplasmic reticulum and/or lysosome).
This suggests that mitochondria are potent integrators of diverse
signaling pathways of apoptosis via gene expression deregula-
tion (p53, bcl-2, bax, myc…), metabolic changes (e.g. intracel-
lular ATP content, ROS and calcium imbalance…), exogenous
stimuli (nutrient deprivation, radiations, xenobiotic…); (ii) is a
checkpoint in the apoptosis process and its induction is
irreversible. In most conditions, MMP is induced and
amplified by a positive amplification loop by Ca2+-induced
Ca2+ release (CiCR) [36], reactive oxygen species (ROS)
generation [37], and caspase activation [38,39], and (iii)
coordinates the degradation phase of apoptosis by releasing
soluble pro-apoptotic factors (Cyt c, AIF, Smac/diablo,
EndoG, Omi/Htra2, pro-caspases…).
As demonstrated in cell-free assays, several cytotoxic drugs
acting directly on MMP have previously been described (for
review, see: [24]). They can be classified as alpha-helicoidal
amphipathic cationic peptides (e.g. Vpr-derived peptides,
(KLAKKLAK)2), steroid-derived-molecules (e.g. resveratrol,
CD437, betulinic acid), BH3-mimetics, PBR-ligands (e.g.
PK11195), VDAC ligands and ANT-ligands (e.g. Verteporfin,
lonidamine, arsenite, CD437, Clodronate, MT21), pro-oxidant
molecules (superoxide, HNE), cationic lipophilic agents (F16,
FTY720), Bcl2 ligand (HA14-1), mtK-ATP openers (diazoxide,
nicorandil, BMS 191095), mtK-ATP blockers (glibenclamide,
5-hydroxydecanoate, MCC-134).
Depending on their structure, some MMP inducers exhibit
anti-tumoral activity in vitro, in animal and/or in human
supporting the idea of targeting the mitochondria for the
modulation of apoptosis as a seductive therapeutic strategy to
treat a wide range of diseases [40].
3. Potential mitochondrial targets
As explained above, the mitochondrion contains numerous
regulatory molecules involved in the control of the energetic
metabolism and intrinsic phase of apoptosis, which constitute
potential therapeutic targets [40]. This applies to key apoptotic
Fig. 1. A model of the mitochondrial membrane permeabilization process and its potential pharmacological targets. Apoptosis can be induced by exogenous stimuli as
well as by endogenous stress signals. The process of membrane permeabilization can be activated directly (by Ca2+, changes of the redox state, the ionic concentration
or the pH) and/or regulated by Bax/Bcl-2 family members. The opening of the permeability transition pore results from the targeting of its various components, and
manifests as a dissipation of the transmembrane inner membrane potential (ΔΨm) and the release of intermembrane soluble pro-apoptotic factors like cytochrome c.
Apoptotic stimuli can also activate the BH3 only proteins (for instance Bid), triggering Bax or Bak oligomerization at the OM where it forms a pore for the release of
pro-apoptotic factors in the cytosol. The various components of the respiratory chain are represented in blue. HK, hexokinase; PBR, peripheral benzodiazepine
receptor; VDAC, voltage-dependent anion channel; CK, creatine kinase; ANT, adenine nucleotide translocator; CypD, cyclophilin D; ROS, reactive oxygen species;
IM, inner membrane; and OM, outer membrane.
1314 E. Jacotot et al. / Biochimica et Biophysica Acta 1757 (2006) 1312–1323executioners (e.g. Bax homologs, constitutive mitochondrial
proteins from the oxidative phosphorylation, the import
machinery as well as from the PTPC…), co-factors of
cytoplasmic or nuclear executioners (pro-caspases, Cyt c, AIF,
EndoG), and to inhibitors of the apoptotic program (e.g. Bcl-2
homologues, smac/DIABLO, IAPs, heat shock proteins). Via a
putative role in the process of mitochondrial matrix swelling,
the recently-identified aquaporin-8 water channel could also
constitute an attractive target [41]. In this review, we will
overview three groups of proteins, Bax/Bcl-2 family members,
proteins from the PTPC and proteins from the respiratory chain
to describe the state of the art of the identification of
pharmacological targets for the conception of potential
therapeutic molecules.
3.1. Bax/Bcl-2 family members: pro- and anti- apoptotic
proteins
3.1.1. Anti-apoptotic members
The overexpression of Bcl-2 was first implicated in the
progression of follicular lymphoma as a consequence of a
chromosomal translocation [42]. Subsequently, the overex-
pression of other anti-apoptotic members of this protein familyhas also been implicated in a variety of human cancers in
correlation with their capacity to inhibit apoptosis at the level of
the mitochondrion [43]. Moreover, numerous cellular stresses,
including DNA damage, hypoxia, UV radiations, and che-
motherapy can be integrated by mitochondria, leading to
irreversible alterations and apoptosis. Thus, the Bcl-2 homo-
logues, localized to mitochondrial membranes, appear to be able
to prevent the hallmarks of themitochondrial dysfunction, i.e. the
loss of ΔΨm, swelling of the matrix, release of intermembrane
space proteins (Cyt c, AIF, Smac/DIABLO, Endo G…, etc.),
generation of ROS, and activation of executioner caspases such
as caspases-3, -7 and -9. Many hypothesis have been launched to
explain their potent inhibitory activity such as oligomerization
[43], pore formation [44], regulation of channel such as VDAC
[45] and/or ANT [46], an increase of cell resistance towards
oxidative stress [47], Ca2+ flux regulation at the endoplasmic
reticulum and the mitochondrial membranes [48–50] and an
effect on the apoptosome formation, a cytosolic complex
constituted by APAF-1, Cyt c, dATP and caspase-9 [51].
3.1.2. Pro-apoptotic proteins
In contrast with anti-apoptotic members (e.g. Bcl-2 and Bcl-
XL), pro-apoptotic proteins of the Bax/Bcl-2 family (e.g. Bax,
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machinery. A wide variety of apoptotic stimuli (e.g. p53-
dependent apoptosis, nuclear stress, redox pro-oxidant stress,
chemotherapy) request the participation of the BH3 family
proteins (listed in Fig. 2). As a result of apoptosis induction,
they become “activated”, and propagate the cell death stimulus
to the core apoptosis machinery [11]. Activation refers generally
to events of dimerization (e.g. Bax), post-translational modi-
fication (e.g. Bad), translocation from cytosol to mitochondria
and endoplasmic reticulum (e.g. Bax, Bid, Bim), homo and
heterooligomerization (e.g. Bak, Bad) [52], but triggering
factors of this activation process as well as the hierarchy of
the associated events remain to be elucidated.
3.1.3. Potential therapeutic molecules targeting Bax/Bcl-2
family members
Because they constitute central actors of the apoptotic
machinery, Bax/Bcl-2 family members appeared rapidly as
attractive candidates for the design of therapeutic molecules.
Several leading laboratories and/or companies developed
strategies to target Bax/Bcl-2 family members either directly
with small molecules, antisense oligonucleotides or molecules
interfering within critical protein–protein interactions.
Thus, Bax/Bcl-2- or Bak/Bcl-XL- heterodimerizing capa-
cities have been extensively used for high-throughput screen-
ing of chemical libraries to identify pro-apoptotic as well as
anti-apoptotic molecules (e.g. [53,54]). For instance, to
identify Bcl-XL antagonists, two high-throughput screens
were generated on the basis of the binding of fluorescein-
labeled peptide the BH3 domain of BAD protein to Bcl-XL
and on an affinity selection/mass spectrometry (ASMS) assay.
Utilizing a screening format of 384-well plate with mixtures of
10 drugs per well, 370,400 compounds were screened in
duplicate and 425 inhibitors with an IC(50) below 100 μM
were identified with the first screening assay. With the secondFig. 2. BH3 domain of pro-apoptotic members of Bax/ Bcl-2 family. The BH3
proteins are all pro-apoptotic and share sequence homology within the
amphipatic alpha-helical BH3 region as shown in the sequences alignment.
Are presented the BH3 domains of the human proteins: Bax, Bcl-2 associated X
protein; Bad, Bcl-2 antagonist of cell death; Bak, Bcl-2 homologous antagonist/
killer; Bid, BH3-interacting domain; Puma, P53 up-regulated modulator of
apoptosis; Noxa, identified (as a mediator of p53-dependent apoptosis) in cells
exposed to noxious stresses; Bim, Bcl-2 interacting mediator of cell death; Bik,
Bcl-2 interacting killer; Hrk, activator of apoptosis harakiri; Bmf, Bcl-2
modifying factor. BH3 peptides could serve as prototypes for pro-apoptotic
molecules as they act directly on isolated mitochondria to induce (outer)
mitochondrial membrane permeabilization.assay, 263,382 compounds were screened and 29 ligands with
affinities below 100 μM were identified. Thus, two novel
classes of Bcl-XL inhibitors were identified by both methods
and confirmed to bind (13)C-labeled Bcl-XL using hetero-
nuclear magnetic resonance spectroscopy [54].
Reed JC et al. developed antisepses oligodeoxynucleotides
specific for sequences in mRNAs from the bcl-2 gene to inhibit
the growth in culture of human leukemia cell lines [55]. The
study led to the cell death through sequence-specific mechan-
isms, with reductions in cellular viability generally lagging the
inhibitory effects on cellular growth by about 2 days, indicating
that these oligodeoxynucleotides can be sequence-specific
inhibitors of leukemic cell growth and survival [55]. Fifteen
years later, bcl-2 antisenses are evaluated in phase III clinical
trials in lymphocytic leukaemia, non-small-cell lung cancer,
advanced malignant melanoma, and multiple myeloma.
Antimycin A has been predicted to interact with the Bcl-2
homology domain 3 (BH3)-binding hydrophobic groove of
Bcl-XL by computational molecular docking analysis [56].
Thus, antimycin A binds competitively to recombinant Bcl-2,
induces mitochondrial swelling and loss of ΔΨm on addition to
mitochondria expressing Bcl-XL After chemical modification,
the 2-methoxy derivative of antimycin A3 does not inhibit
cellular respiration, but still retains toxicity for Bcl-XL-
overexpressing cells, mitochondria and Bcl-XL-containing
proteoliposomes [56].
Altogether, these studies validate the interest of novel
therapeutic agents derived from Bcl-2/Bax family proteins to
treat pathologies resulting from an excess or a defect in
apoptosis and support the various clinical studies of phase I and
II currently undertaken.
3.1.3.1. The permeability transition pore. The permeability
transition pore, PTPC, is a mitochondrial polyprotein complex
(MW≈600 kDa) involved in the regulation of mitochondrial
matrix homeostasis It is built-up at the mitochondrial contact
sites, requiring an association with IM and OM lipids such as
cardiolipin and cholesterol to function properly. Its opening as
a large unspecific channel leads to the mitochondrial transition
permeability that corresponds to an increase in the perme-
ability of the IM, permitting the influx or efflux of any
molecule of MW≤1500 Da [57]. In physiological conditions,
the PTPC pore is regulated by endogenous signals as diverse
as: the ΔΨm, matrix pH, the concentration of divalent cations
(Ca2+, Mg2+), the redox equilibrium (ROS, thiols), and the
matrix volume [58]. As measured by electrophysiology,
mammalian PTPC exhibits multiple conductance states,
suggesting that the channel is composed of several cooperating
subunits [59].
However, in stress conditions, mitochondrial transition
permeability can be deleterious to the mitochondrial physiology
by the initiation of the mitochondrial phase of apoptosis,
necrosis or autophagy [60]. Thus, as a consequence of the long
lasting opening of PTPC, the mitochondrial matrix swells, the
ΔΨm dissipates and the outer membrane (OM) ruptures locally
triggering the release of apoptogenic proteins into the cytosol
[61]. Upon apoptosis initiation, PTPC opening can precede Bax
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concomitantly with pro-apoptotic Bax/Bcl-2 family members
(Bax, Bid…) translocation, but usually before release of Cyst c
and AIF from mitochondria (for review: [63]). Thus, irrespec-
tive to the hierarchy of events, a new class of channels can be
formed via cooperation between Bax and ANT, and lead to
MMP induction and cell death [64].
The composition of PTPC is dynamic and may evolve in
response to the energetic demand of the cell and to apoptosis.
This may result from the remodeling of mitochondrial cristae
and of contact sites during the process of apoptosis induction
[65]. From biochemical and functional studies using purified
proteins reconstituted in artificial biomembranes (e.g. lipo-
somes or black lipid membranes), two models of structure/
function relationship of PTPC emerged. One model proposes
that three proteins constitute PTPC: the adenine nucleotide
translocator (ANT, in the IM), voltage-dependent anion channel
(VDAC, in the OM) and cyclophilin D (CypD, in the matrix)
[66–68], and alternative models suggest a variable complex
composition depending on tissue, differentiation, metabolic
status and development state [69,70]. This is notably the case of
the composition of ATP synthasome and various complexes
involving ANT, VDAC and CypD that varies upon the
energetic activity of the mitochondrion [69,70]. The core of
PTPC would be constituted by ANT, VDAC and CypD and
regulated by, at least, the peripheral benzodiazepine receptor
(PBR, in the OM), hexokinase (HK, in the cytosol), and
creatine kinase (CK, in the intermembrane space) [71] and GST
[72].
However, as isolated liver mitochondria from ANT1−/−
ANT2−/−mice still undergo PT for high doses of calcium, it has
been proposed from genetic studies that, at least, ANT1 and
ANT2 isoform knockout could be compensated by another IM
protein (e.g. ANT4, another mitochondrial carrier protein, an
unknown channel) [73], and for critical commentary [74]).
Moreover, three genetic studies confirmed that cyclophilin D
participates to the PTPC function during necrosis and
ischemia–reperfusion [75–77]. It is important to note that, in
both structure/function models, some proteins are anti-
apoptotic (HK, CK, CypD), whereas others are pro-apoptotic
(ANT, VDAC, PBR) favoring the closed or the open state of
PTPC, respectively, and thus enabling a tight regulation of the
MMP process. In addition, PTPC function could be modulated
by physical interactions of some of its members with onco-
and anti-oncoproteins from the Bax/Bcl-2 family. ANT,
VDAC and HK (glucokinase in liver) were identified as
ligands of Bax, Bcl-2, Bid, Bcl-XL, Bad and Bak [45,46,78–
81]. Among these proteins, some members of Bax/Bcl-2
family were shown to be regulators of channel activity of ANT
and VDAC, as well as modulators of the ADP/ATP translocase
activity of ANT [45,64,82]. Recently, Machida et al. have
found that inactivation of endogenous CypD by small
interference RNA or cyclophilin inhibitor releases hexoki-
nase-II from mitochondria and enhances Bax-mediated
apoptosis [83]. These authors further proposed that mitochon-
drial bound hexokinase II plays an essential role in the CypD
mediated anti-apoptotic effect.Recently, extensive study of the role and function of ANT
in MMP led to the proposal, that ANT could be a
therapeutic target [84]. To mimic membrane insertion and
mitochondrial compartimentation, several functional assays
were designed and based on the reconstitution of rat heart
purified ANT into artificial bilayers such as liposomes.
Various substrates, such as calcein, 3H glucose, 3H inulin,
malate, or 4-methylumbelliferyl phosphate (MUP), were
encapsulated in ANT-containing proteoliposomes and their
release studied as a quantitative measure of ANT pore
opening [85,86]. This methodology allowed the evaluation of
the capacity of various agents known to induce MMP, to
permeabilize selectively ANT-containing liposomes (e.g.
proteins, peptides, lipids, pro-oxidants and chemotherapeutics
agents). Thus, the effects of endogenous components
involved in the activation cascade of apoptosis and/or
xenobiotics were characterized and their inhibitory profile
determined. These compounds include pro-apoptotic members
(Bax, Bid) of the Bax/Bcl-2 family [46,87], pro-oxidants
agents (diazenedicarboxylic-acid-bis-5N, N-dimethylamide
(diamide), dithiodipyridine (DTDP), or bis-maleimido-hexane
(BMH), tert-butylhydroperoxide (t-BHP), nitric oxide (NO)
[88,89], viral protein R (Vpr from HIV-1) and derived
peptides [90,91], a viral mitochondria-localized inhibitor of
apoptosis (vMIA) from cytomegalovirus [92], short chain
fatty acids [93], as well as chemotherapeutic agents (arsenite,
CD437, lonidamine and Verteporfin) [94,95]. Although we do
not exclude that these molecules can have additional
intracellular target, they can act directly on ANT to convert
it into a non-specific pore. This assumption is supported by
the fact that ATP and ADP (endogenous ligands of ANT),
bongkrekic acid, cyclosporin A and m-val-cyclosporin A, and
Bcl-2 prevent the permeabilizing effects of these molecules in
ANT-proteoliposomes and in intact cells. Altogether, the
diversity of the molecules suggested that ANT could be a
potential target for apoptosis modulation, what has been
confirmed in three acute pathologies in mice [96], but awaits
in vivo confirmation in relevant human physio-pathological
models. Interestingly, the structure of ANT in complex with
carboxyatractyloside has been resolved recently [97], what
should help the future conception of molecules able to bind
ANT within its key domains (sulfhydril amino acids, hydro-
philic loops, inhibitors binding pockets…, etc.).
Despite the structure of the PTPC channel remains elusive,
VDAC is currently considered to be the protein constituting
the OM channel of the complex. In vitro, it has been shown
that VDAC pro-apoptotic function can be modulated by
various stimuli, including the anion superoxide, Bax, Bcl-XL,
and a small molecule, Ro 68–3400 (for review: [98]). Other
PTPC members, such as PBR, HK, CypD and CK being
rather regulators than true components of the PTPC channel,
should also be considered in a therapeutic perspective.
However, all these proteins are not ubiquitously expressed
and are usually involved in specific pathologies, such as
Lupus erythematosus (PBR), some cancers (HK) and
mitochondrial diseases (CK), limiting their application
domains to specific pathologies.
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The respiratory chain is composed of four proteic complexes
(Fig. 3). These complexes are embedded within the inner
mitochondrial membrane and associated with two cofactors,
coenzyme Q or ubiquinone and cytochrome c, that allow the
interface between all the complexes. The function of the
respiratory chain is to collect the energy from the oxidation of
NADH and FADH2 to generate a proton gradient, an electron
flux, and ATP synthesis. The use of several natural or chemical
functional inhibitors of the various complexes (rotenone, KCN,
oligomycin…) has allowed the understanding of the coupled
function of these complexes and the quantification of energy
generated for the general cell metabolism.
Mitochondrial defects have been implicated in a wide variety
of degenerative diseases, in aging, and in cancer [76]. Recently,
clinical studies revealed an interplay between mutations in the
mitochondrial and nuclear genomes, and a role of mitochondrialFig. 3. Comparison of the half-maximal effects (ED50) of different peptides and
small molecules in mitochondrial swelling and ΔΨm loss assays. Liver
mitochondria were isolated from 3 to 4 weeks old BALB/c mice as previously
described [124]. Freshly isolated mitochondria were distributed in 96-well plates
in a medium containing 200 mM sucrose, 5 mM succinate, 10 mM Tris–MOPS
(pH 7.4), 1 mMH3PO4, 2 μMRotenone, and 10 μMEGTA, supplemented with
1 μM rhodamine 123 (Rh123; Molecular Probes™), followed by the addition of
serial dilutions of compounds. Then, absorbance at 545 nm and Rh123
fluorescence (excitation 485 nm, emission 535 nm) are recorded during 30
cycles of 1 min using a fluorescence multi-well plate reader (Genios, Tecan®,
Männedorf, Switzerland). CaCl2 (30 μM) and mClCCP (20 μM) treatments
were considered as 100% baseline for the swelling and ΔΨm loss, respectively.
ED50 on mitochondrial swelling and ΔΨm were extrapolated from the dose–
response curves (log 2 dilutions). Results are the mean of three independent
experiments (SD were negligible). Note: compounds were added to mitochon-
dria without any calcium pre-pulse.respiratory chain in cellular energy production, of ROS
generation, and of the induction of apoptosis. The importance
and relationship of these functions are now studied in mouse
models of mitochondrial disease [99]. These models may allow
to identify key actors (genes and/or proteins) and to dissect
essential regulatory mechanisms.
Several approaches have linked the cellular respiratory
activity to apoptosis and notably, to the choice between
apoptosis and necrosis via the level of intracellular ATP
[100]. Moreover, using human myelogenous leukemia cells, it
has been demonstrated that respiratory function is essential for
tumor necrosis factor-induced Cyt c release. In a cell free
system using mitochondrial fraction from the same cells,
initiation of respiration by substrates for complexes I, II, and III,
but not IV, released Cyt c, suggesting that reduction of
coenzyme Q or complex III is essential for Cyt c release [101].
Nevertheless, one key issue for the identification of pertinent
therapeutic targets would be to discriminate direct effects on
respiratory chain's functions from indirect effects altering other
key mitochondrial structures, such as the import machinery or
the PTPC.
3.2.1. Complexes I and II as direct functional targets in the
pro-apoptotic cascade
Two complexes of the respiratory chain, I and II, constitute
direct functional targets of the executioner caspase-3, a pro-
apoptotic protease. Thus, the dysfunction of these two
complexes leads to the dissipation of ΔΨm, the generation of
ROS and contributes to the dismantling of the cell via a retro-
amplification loop following the cytosolic Cyt c release [39].
Indeed, caspase-3 was inefficient to induce mitochondrial
alterations when added directly onto intact isolated mitochon-
dria requiring a permeabilizing event (e.g. Bid addition) to
access to the IM. Thus, in apoptotic HeLa or Jurkat cells,
caspase-3 disrupts oxygen consumption induced by complex I
and II substrates, but not that induced by electron transfer to
complex IV. In addition, complex III activity measured by Cyt c
reduction remains intact after caspase-3 treatment [39]. These
data are compatible with previous studies showing that in Fas-
induced or TNF-induced apoptosis a reduction of complex I and
II activity can be measured ([102,103], but these studies did not
reveal the proteolytic substrate of caspase 3 that is responsible
for this pro-apoptotic effect.
3.2.2. Complex I as an indirect regulator of MMP
Rat skeletal muscle mitochondria can undergo a mitochon-
drial permeability transition following Ca2+ uptake in the
presence of Pi. However, in this case, this permeability transition
can be dramatically modified by the substrates used for
energization and the rate of electron flow through complex I
[104]. This increased sensitivity of PTPC opening does not
depend on differences in membrane potential, matrix pH, Ca2+
uptake, oxidation–reduction status of pyridine nucleotides or
production of H2O2 In addition, ubiquinone 0 at concentrations
which partially inhibit respiration and do not depolarize the IM,
inhibits the PTPC opening [105,106], suggesting a site of
regulation of the PTPC by complex I, and drawing perspectives
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vincing studies were led with isolated mitochondria, waiting now
for a molecular identification of the target site within PTPC.
In summary, as respiration is a crucial mitochondrial
function, it is intuitively a potential mechanism to target for
apoptosis modulation, notably via the modulation of ROS
generation, and will undoubtedly furnish valuable therapeutic
tools as soon as key components will be identified and
characterized. One major issue will be the specificity of the
pharmacological agent that should kill only some cells, and not
all respiring cells.
4. Peptides targeting the mitochondrion to induce apoptosis
As our knowledge of apoptosis deregulation increases, the
possibilities for pro and anti-apoptotic therapeutics seems not
only promising, but a realistic adjunct to current treatments.
Some peptides, for instance BH3-derived peptides, have
reached the proof of principle step and can be either used as a
basis for large screening using small molecule libraries or
alternatively directly optimized as a backbone for the design of
new therapeutically functional pseudopeptides. This later drug
development strategy has strongly evolved during the last two
decades and is now proved to be efficient, for instance in the
field of opioid peptide-based analgesics, or HIV-1 host–cell
attachment and entry) Indeed, structures of peptidic leads can be
optimized in term of structure–efficacy relationships, con-
formation and stability in biological fluids and ease of synthesis,
keeping in mind future scale-up requirement (Table 1).
Three examples of pro-apoptotic peptides have been selected
to illustrate the potential use of peptides to modulate apoptosis
via an effect on the mitochondrion. These peptides can be easily
obtained by chemical synthesis and are in one case non-natural
and in the other cases, derived from endogenous proteins (Bax/
Bcl-2) and a viral protein, Vpr.
4.1. Anti-cancer activity of targeted pro-apoptotic peptides
Tumor development is largely dependent of oxygen and
nutrient supply, which is provided by blood vessels irrigating
the tumoral tissue. Thus, cancer growth requires continuous
colonization by neo-vessels, a process which is called tumorTable 1
Approaches for optimization of peptide-based drugs
• Structural analysis (RMN, RX) and computer-assisted molecular modelization
• Rationale and systematic (“alanine scanning” or “multi-scan” approaches)
amino-acid substituting
• Insertion of amino acids analogs (N-methyl amino-acids, D-amino-acids, non-
naturals residues), blocking of N-ter and C-ter ends (acylation, amidation), or
cyclization (for instance S–S, CO–NH or C–C bonds)
• Improve linker structure of bifunctional/chimeric peptides through amino-
acids changes or replacement by cleavable bonds (disulfide-linked
conjugates)
• Peptide backbone modifications including: carbon–carbon double bonds
(oleofinic constraints), rings (benzene, carbohydrates, lactams and azoles),
bio-isosteric peptide bond replacements (for instance retro-inverso, methylene
amino, or tetrazole isostere), and foldameres (β-peptides, γ-peptides, and
isosteric backbones)angiogenesis. Selective inhibition of tumor angiogenesis thus
presents many attractive features for oncology: as it is a very
general process, and relies on normal untransformed host cells
(mainly endothelial cells, which are the forerunners of tissue
colonization during angiogenesis), it could be applied to many
types of cancers, and avoid many hurdles of standard
chemotherapies, such as the diversity of tumorisation pro-
cesses, heterogeneity within a given tumor, genetic or
chromosomal instability, and drug resistance. Antiangiogenesis
is expected to be particularly efficient against metastasis
development. Thus, this strategy raised an enormous interest,
with various scientific strategies [107]. It is worth to note that
among products in clinical or preclinical development for
antiangiogenesis, most are so called “ vasculostatics”, i.e.
inhibiting vessel growth, such as tyrosine kinase inhibitors,
metalloproteinases inhibitors, antisenses, or endothelial cell
surface receptors (e.g. integrin) blockers. Vasculotoxic com-
pounds would be more interesting, as able to disrupt
established vessels, and thus destroying tumors areas depend-
ing on their blood supply. However, most of these are in the
early preclinical stages, mostly being of the targeted toxin type.
In this context, Ellerby et al. [108] elaborated a computational
approach to design short peptides composed of two functional
domains, one a tumor blood vessel ‘homing’ motif and the
other a programmed cell death-inducing sequence and
synthesized them by chemistry [108]. One example of such
peptide is the sequence CNGRC-GG-D(KLAKLAK)2. The
‘homing’ domain (CNGRC) was chosen to render the peptide
specific of targeted cells and to allow its internalization. In
addition, the pro-apoptotic domain (D(KLAKLAK)2) was
designed to be toxic only when internalized into targeted
cells by the disruption of mitochondrial membranes. Thus, the
prototypes (only 21 and 26 residues) were selectively toxic to
angiogenic endothelial cells, permeabilized mitochondrial
membrane, and activated caspases to induce cell death by
apoptosis [108]. Interestingly, these peptides showed anti-
cancer activity in mice. Inoculation of the targeted pro-
apoptotic peptide and a control non-targeted ‘mimic’
CARAC-GGD(KLAKLAK)2 peptide in vivo, in nude mice
bearing human MDA-MD-435 breast carcinoma xenografts
revealed that the pro-apoptotic peptides inhibited tumor growth
and metastasis by inducing apoptosis and necrosis, without
detectable toxicity and immunogenicity [108]. Those data, and
subsequent studies demonstrating selective destruction of
prostate carcinoma through similar strategy [109], constitute
a proof of principle for the development of bi-functional
peptides that trigger specifically neo-endothelia's mitochon-
drial membrane permeabilization and apoptosis.
Future will tell if such compounds can be sufficiently
optimized to combine strong efficacy, with acceptable safety
and ADME criteria, together with successful process develop-
ment for large-scale production.
4.2. Homology domains of Bax/Bcl-2 family members
Bax/Bcl-2 family members sequences can be composed of 1
to 4 homology domains (BH1 to BH4) [110]. The various BH3
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activity of the members, whereas the BH4 domains, as present
only in anti-apoptotic proteins, would be associated to the
inhibition of cell death.
Thus, BH3 peptides from pro-apoptotic members have
been extensively studied as inducers of apoptosis in vitro but
their precise mechanisms of action are still debated [30]. The
proof of concept that BH3 mimetics can be designed that
initiate apoptosis at definable points in the genetic pathway
was published by Letai et al. [30]. This work described
synthetic BH3 peptides that initiated cell death either by
activating proapoptotic members or by counteracting anti-
apoptotic members, displacing BH3 domains from their
pockets. In a fusion strategy, the BH3 domain of Bak has
been linked to a viral protein VP22 [111]. The BH3-VP22
protein was associated into oligonucleotides containing
particles that entered cells and remained stable in the
cytoplasm without toxicity. Via light activation, the fusion
protein entered into cell, localized in the cytoplasm and the
nucleus and induced the subsequent cell death by apoptosis. In
control experiments, particles containing a mutant BH3
peptide, although indistinguishable in cell uptake and
regulated release, showed no apoptotic effect. However,
other studies utilizing chimeric cell permeant BH3 peptides
have suggested that some of the cytotoxic effects were
independent of direct interaction with Bcl-2 family members
[112,113]. BH3 peptides are cationic amphipatic α-helices and
consequently may act directly on mitochondrial membranes
either through interaction(s) with sessile membrane proteins
(for instance VDAC or ANT) or through lipid–peptide
interactions leading to membrane disruption. Taking into
account these « secondary » mechanisms of action, two
opposite drug development strategies can be proposed : (1)
use peptides, pseudo-peptides or small molecules selected to
bind selectively Bcl-XL/Bcl-2, with considerable attention to
have low toxicity onto mitochondrial membranes, (2) or, in
contrast, to select peptides or pseudo-peptides with a very
strong capacity to disrupt mitochondrial membranes and to
combine them with a targeting strategy, as discussed in the
previous section ([KLAKKLAK]2 peptide) and in the next
section (Vpr derived peptides). In line with the first, Bcl-2/
Bcl-XL-based strategy, many groups have tried to improve
peptide function by stabilizing the α-helical conformation of
BH3 peptides (for review: [114]). An interesting example was
obtained by Walensky et al. by the use of ‘hydrocarbon
stapling’ to stabilize the alpha-helix of a Bid mimetic peptide
and obtain a cell-permeable molecule that kills leukemia cells
in vitro and in vivo [115]. This modification enhanced affinity
for Bcl-2, protease resistance, and leukemia cell line toxicity
in vitro. The compound was able to induce Cyt c release
from isolated mitochondria in a Bak-dependent fashion.
Moreover, mice bearing leukemia cell line xenografts had
statistically significant survival improvement of 6 days.
Although this observed efficacy with this compound remains
insufficient to reach the clinical step, future optimized BH3-
based compounds, possibly combined with conventional
therapy, may provide a therapeutic benefit.In another approach, Rosenberg, Fesik and co-workers used
a high-throughput screening combined with iterative modula-
tion of chemical structure based on NMR to find small
molecules that bind Bcl-XL. Two low-affinity ligands, a
substituted biphenyl and a tetrahydronaphthol, were found to
bind in adjacent pockets of the Bcl-XL groove. Cycles of
medicinal chemistry improved the affinity by connecting the
two sites through a sulfonamide linker and introducing
functional groups that reduced binding to human serum
albumin. The resultant compound, ABT-737 (Abbott Labora-
tories), displace BH3 domains from Bcl-2, Bcl-XL, and Bcl-w
with an IC50 of no more than 1 nM. ABT-737 requires Bax and
Bak for cell killing, and assays showed that ABT-737 enhanced
radiation and traditional cytotoxic chemotherapeutics killing of
several tumor cell lines. ABT-737 induced apoptosis in a
primary culture of cells derived from two kinds of hemato-
logical malignancies known to express high levels of Bcl-2-
follicular lymphoma and chronic lymphocytic leukemia—with
the dose at which 50% cell killing occurs being in the 10 nM
range. When administered daily for 3 weeks (intraperitoneally
at 75–100 mg/kg), ABT-737 have significant activity in several
mouse xenograft models of lung cancer and lymphoma [116].
Most impressive is the complete regression of tumor observed
in small-cell lung cancer (SCLC)-xenografted mice. Although
side effects including lymphopenia and thrombocytopenia were
noted in mice this small BH3 mimetic may be useful for the
treatment of lymphoma and SCLC as monotherapy and a wide
variety of cancers when given in combination with chemother-
apy or radiation.
Bcl-2 homology domains have been also used to inhibit
apoptosis. For instance, a pioneering study form the group of
Tsujimoto showed that the BH4 domain of Bcl-XL fused to the
protein transduction domain of HIV Tat efficiently prevented
apoptotic cell death, possibly through VDAC closure [117]. In
vitro studies extended the anti-apoptotic potential of BH4
peptides to various human tissues including islet [118] and
coronary endothelial cells [119]. Finally, in rat models of
cardiac ischemia–reperfusion in vivo, X-ray small intestine
induced apoptosis or Fas-induced fulminant hepatitis, Tat-BH4
peptides proved to be potent apoptosis inhibitors, and to
suppress heart failure and (partially) hepatic damages [120],
suggesting a potential interest of this molecule for further (pre-)
clinical studies.
4.3. Peptides derived from viral protein R (Vpr)
Viral protein R (Vpr, 96 aa) is a small accessory protein of
HIV-1 (for review see: [121]). Taking advantage of the basic
study of Vpr-induced apoptosis mechanisms, it has been
possible to identify the mitochondrio-toxic domain of Vpr as
located within the C-terminal part of protein (aa71–82), and to
derive several pro-apoptotic peptides from this sequence as
well as inactive mutant. This showed that when Vpr is added
to intact various type of cells (not only lymphoid cells) or
purified mitochondria, it induces hallmarks of MMP: a rapid
dissipation of ΔΨm and the mitochondrial release of
apoptogenic proteins such as Cyt c or AIF via a direct
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artificial bilayers containing the purified PTPC or ANT, Vpr
favors the appearance of a conductance indicating the opening
of a large channel in the presence of Bax. The c-terminal
moiety of Vpr (Vpr52–96) binds to purified ANT, as well as a
molecular complex containing ANT and VDAC. Interestingly,
yeast strains lacking ANT or VDAC are less susceptible to
Vpr-induced killing than control cells yet recover Vpr
sensitivity when retransfected with yeast ANT or human
VDAC [91]. Initial surface plasmon resonance studies
identified a domain of ANT able to interact with Vpr52–96
as the 104–116 aminoacids sequence, i.e. a hydrophilic loop
facing the intermembrane space [91,122]. To specify this
interaction, Sabbah et al., synthesized fragments of both
proteins demonstrated that in vitro, the [27–51] and [71–82]
Vpr peptides bind to a region encompassing the first ANT
intermembrane space loop and part of its second and third
transmembrane helices [123]. These authors also constructed a
three-dimensional model of the Vpr–ANT complex in which
the N-terminus of Vpr plunges in the ANT cavity whereas the
Vpr C-terminal extremity is located at the surface of the ANT
allowing possible interactions with a third partner. These
results could be used to design molecules acting as pro-
apoptotic Vpr analogs or as apoptosis inhibitors preventing the
Vpr–ANT interaction. Key features of Vpr toxicity appeared
to reside within its conformation in amphipatic helix and
within positively charged residues, as shown by the abolish-
ment of mitochondriotoxicity by replacement of any of the
arginines (R73, R77, R80) by alanine residues, or by insertion
of D-proline to impose non helical conformation [67,68]. Our
recent SAR study indicates that a modified D version of the
cysteine-devoid peptide Vpr67–82 (DVpr67–82[C76S]) is a
very potent inducer of the mitochondrial swelling and ΔΨm
loss (Fig. 3). In vivo studies are ongoing, using Vpr-derived
peptides linked with cell-penetrating sequences or homing
sequences to determine the capacity of such molecules to
influence the outcome of tumor growth.
5. Conclusion
Apoptosis is a physiological mechanism that can be altered
in a wide range of human diseases. Thus, a slight deregulation
of apoptosis can lead to an accumulation of mutated or
unwanted cells as well as an excessive depletion of a particular
cell type. During apoptosis program, mitochondria play a
decisive role acting as an integrator of multiple intracellular
signaling pathways and a potent coordinator of the final
degradation phase [24]. Thus, targeting the mitochondria to
modulate cell death has focused the interest of the pharmaceu-
tical research leading to the investigation of diverse strategies
such as anti-sense oligonucleotides or small molecules. As
many effectors of apoptosis are proteins and as they are in
dynamic interactions with each other, one alternative possibility
is to exploit the potential of chemistry to derive peptides from
existing molecules (e.g. Bax/Bcl-2 members, Vpr) or to
synthesize novel sequences from computational methods.
Since peptides and pseudo-peptides cost of synthesis aredecreasing and their toxicity is generally limited, once their in
vivo stability and bio-disponibility will be optimized, this type
of therapeutic molecules should be promising in terms of
selectivity, specificity and efficiency. We anticipate that major
advances in the mitochondrial apoptosis field will be made in
the future and will help to define new molecules for the
treatment of challenging human diseases.
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